Stock Repurchase Program Initiated by Prenetics Global (NASDAQ:PRE) Board of Directors

Prenetics Global (NASDAQ:PRE) announced that its Board of Directors has initiated a share buyback program on Friday, March 6th, RTT News reports. The company plans to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 15.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Prenetics Global Stock Up 18.1%

NASDAQ PRE opened at $17.80 on Friday. The stock’s 50-day simple moving average is $17.69 and its two-hundred day simple moving average is $14.57. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $22.86. The company has a market capitalization of $299.57 million, a price-to-earnings ratio of -4.43 and a beta of 0.36.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.22. The firm had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $36.15 million. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%. On average, equities analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wall Street Zen cut Prenetics Global from a “buy” rating to a “hold” rating in a research report on Monday, February 16th. Roth Mkm began coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.00.

More Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Board-approved $40 million share buyback — authorization to repurchase up to roughly 15.8% of outstanding stock, a strong signal management views the shares as undervalued and a likely direct support to the share price. Prenetics stock surges after $40M buyback program announced Prenetics Authorizes $40 Million Share Repurchase Program Prenetics Global Shares Jump on $40M Repurchase Program RTT News – Stock Buybacks
• Neutral Sentiment: Recent quarterly results showed an earnings beat (EPS loss of $0.27 vs. consensus -$0.49) and revenue slightly above estimates ($36.6M vs. $36.15M), indicating improving near-term performance but the company remains unprofitable. MarketBeat – Prenetics latest results
• Negative Sentiment: Company still posts large negative margins (net margin ~-61%) and negative ROE; analysts forecast material full-year losses (consensus ~-3.3 EPS). The buyback will consume cash and investors should watch the balance sheet and buyback execution risk. MarketWatch – Prenetics Repurchase Program

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.